Previous 10 | Next 10 |
BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in SHAPE, a Ph...
Topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 LIFT-AD Phase 3 Alzheimer’s disease study sample size increased to strengthen statistical power of co-key secondary endpoints and enhance the potential for a single pivotal clinical study Mi...
Athira Pharma (NASDAQ:ATHA): Q3 GAAP EPS of -$0.42 beats by $0.08. Press Release. For further details see: Athira Pharma EPS beats by $0.08
– Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates and baseline data from ATH-1017’s ongoing Phase 2 a...
Athira Pharma (ATHA -0.2%) says it will release top-line data on its ACT-AD study, a phase 2 trial of its Alzheimer's candidate ATH-1017, in 1H 2022. In a presentation at the 2021 Clinical Trials on Alzheimer’s Disease Conference, Chief Medical Officer Hans Moebius said that in bo...
– Balanced baseline characteristics in ACT-AD and LIFT-AD to date – – Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage bi...
Neurologist Dr. John Michael Olichney to discuss utility of P300 to assess cognitive function Webinar to be held Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET BOTHELL, Wash., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biop...
Shares of biopharmaceutical company Athira Pharma (NASDAQ: ATHA) are up close to 13% as of 11:19 a.m. EDT on Friday after the company announced it had finished enrolling participants in its ACT-AD clinical trial for ATH-1017, a therapy for mild to moderate Alzheimer's diseas...
-Topline data targeted for 1H22- BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced today tha...
Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas’s Doctoral Research Conference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA)...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...